These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 6600195

  • 1. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
    Kurata S, Tsuchiya T, Norimura T, Yamashita U.
    J Immunol; 1983 Jan; 130(1):496-500. PubMed ID: 6600195
    [Abstract] [Full Text] [Related]

  • 2. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H, Fujiwara H, Takai Y, Izumi Y, Sano S, Tsuchida T, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [Abstract] [Full Text] [Related]

  • 3. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H, Takai Y, Sakamoto K, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S, Yamamoto H, Fujii Y, Arai S.
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [Abstract] [Full Text] [Related]

  • 5. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K, Fujiwara H, Nakajima H, Yoshioka T, Takai Y, Hamaoka T.
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [Abstract] [Full Text] [Related]

  • 6. Effector mechanism of tumor immunity in murine plasmacytoma.
    Chen YH, Anderson AB.
    Cancer Res; 1988 Mar 15; 48(6):1398-403. PubMed ID: 3257896
    [Abstract] [Full Text] [Related]

  • 7. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S, Fujiwara H, Yamane Y, Sano S, Nakajima H, Izumi Y, Arai H, Kawanishi Y, Tsuchida T, Hamaoka T.
    Jpn J Cancer Res; 1986 Feb 15; 77(2):182-9. PubMed ID: 3082830
    [Abstract] [Full Text] [Related]

  • 8. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E, Wise JA, Dray S, Mokyr MB.
    Cancer Res; 1989 Sep 15; 49(18):5007-15. PubMed ID: 2788494
    [Abstract] [Full Text] [Related]

  • 9. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K.
    Cancer Res; 1993 Jan 01; 53(1):106-11. PubMed ID: 8093229
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Virus-dependent cytostatic activity to mammary tumor cells of lymphocytes from normal mice.
    Gillette RW, Lowery LT.
    Cancer Res; 1976 Nov 01; 36(11 Pt 1):4008-14. PubMed ID: 184922
    [Abstract] [Full Text] [Related]

  • 12. Effector mechanism in antitumor activity of monoclonal antibodies produced against an ascitic mouse mammary tumor.
    Seto M, Takahashi T, Nakamura S, Saito M, Hara T, Nishizuka Y.
    Cancer Res; 1986 Apr 01; 46(4 Pt 2):2056-61. PubMed ID: 3004718
    [Abstract] [Full Text] [Related]

  • 13. Rejection of syngeneic tumor cells by the interaction of Lyt-1+ T lymphocytes and macrophages.
    Mitani M, Matsumoto T, Mori K, Miake S, Himeno K, Nomoto K.
    J Clin Lab Immunol; 1985 Oct 01; 18(2):97-101. PubMed ID: 3935795
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY, Howard JG, Hale C.
    J Immunol; 1984 Jan 01; 132(1):456-61. PubMed ID: 6228580
    [Abstract] [Full Text] [Related]

  • 16. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
    Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S.
    J Immunother; 2001 Jan 01; 24(2):114-21. PubMed ID: 11265768
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
    Izumi Y, Tsuchida T, Okuno K, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1985 Sep 01; 76(9):863-70. PubMed ID: 3932286
    [Abstract] [Full Text] [Related]

  • 19. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
    Fuyama S, Yamamoto H, Arai S.
    Cancer Res; 1985 Sep 01; 45(9):4103-8. PubMed ID: 3875404
    [Abstract] [Full Text] [Related]

  • 20. In vitro induction of polyclonal killer T cells with 2-mercaptoethanol and the essential role of macrophages in this process.
    Igarashi T, Okada M, Kishimoto T, Yamamura Y.
    J Immunol; 1977 May 01; 118(5):1697-703. PubMed ID: 67145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.